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Summary
Background Whether HIV infection is associated with risk of death due to COVID-19 is unclear. We aimed to 
investigate this association in a large-scale population-based study in England.
Methods We did a retrospective cohort study. Working on behalf of NHS England, we used the OpenSAFELY platform 
to analyse routinely collected electronic primary care data linked to national death registrations. We included all 
adults (aged ≥18 years) alive and in follow-up on Feb 1, 2020, and with at least 1 year of continuous registration with a 
general practitioner before this date. People with a primary care record for HIV infection were compared with people 
without HIV. The outcome was COVID-19 death, defined as the presence of International Classification of Diseases 
10 codes U07.1 or U07.2 anywhere on the death certificate. Cox regression models were used to estimate the 
association between HIV infection and COVID-19 death; they were initially adjusted for age and sex, then we added 
adjustment for index of multiple deprivation and ethnicity, and then for a broad range of comorbidities. Interaction 
terms were added to assess effect modification by age, sex, ethnicity, comorbidities, and calendar time.
Results 17 282 905 adults were included, of whom 27 480 (0·16%) had HIV recorded. People living with HIV were 
more likely to be male, of Black ethnicity, and from a more deprived geographical area than the general population. 
14 882 COVID-19 deaths occurred during the study period, with 25 among people with HIV. People living with HIV 
had higher risk of COVID-19 death than those without HIV after adjusting for age and sex: hazard ratio 
(HR) 2·90 (95% CI 1·96–4·30; p<0·0001). The association was attenuated, but risk remained high, after adjustment 
for deprivation, ethnicity, smoking and obesity: adjusted HR 2·59 (95% CI 1·74–3·84; p<0·0001). There was some 
evidence that the association was larger among people of Black ethnicity: HR 4·31 (95% CI 2·42–7·65) 
versus 1·84 (1·03–3·26) in non-Black individuals (p-interaction=0·044).
Interpretation People with HIV in the UK seem to be at increased risk of COVID-19 mortality. Targeted policies 
should be considered to address this raised risk as the pandemic response evolves.
Funding Wellcome, Royal Society, National Institute for Health Research, National Institute for Health Research 
Oxford Biomedical Research Centre, UK Medical Research Council, Health Data Research UK.
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Introduction
Since it emerged in late 2019, severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), the virus that 
causes COVID-19, has infected more than 60 million 
people worldwide, causing more than 1·4 million deaths 
as of November, 2020.1 Older age and male sex have been 
strongly associated with more severe outcomes; several 
comor bidities, including those that involve immuno-
supp ression, also seem to be associated with higher risk 
of COVID-19 death.2 However, little evidence exists on 
how HIV infection affects risk of poor outcomes from 
COVID-19.3 
There is mixed evidence on the contribution of HIV 
to previous respiratory virus epidemics. HIV has been 
asso ciated with a higher risk of severe outcomes from 
respir atory infections, including seasonal influenza,4,5 
and people living with HIV at any stage of infection are 
con sidered a clinical risk group in seasonal influenza 
vaccin ation guidance in the UK.6 However, the contri-
bution of HIV infection to outcomes during the 2009 
H1N1 influ enza pandemic was unclear, with no sub-
stantive evidence that HIV-infected individuals were at 
increased risk of being infected or had worse outcomes, 
unless at an adv anced stage of immunosuppression.7 
Little evidence from the SARS-CoV-2 pandemic exists. 
A large population-based cohort study in South Africa8 
found COVID-19 mortality risk among people living 
with HIV to be double the risk of those without HIV. 
A high prevalence of critical illness was observed among 
HIV-infected patients with COVID-19 in Madrid, Spain, 
alth ough there was no non-HIV com parison group.9 
Other small studies of hos pitalised patients have not 
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detected any increased risk of severe outcomes in people 
living with HIV.10,11
We therefore aimed to investigate the association 
between HIV infection and COVID-19 death using 
population-based data from England.
Methods
Study design and population
A retrospective cohort study comparing the risk of 
COVID-19 death among people living with and without 
HIV was done within OpenSAFELY, a new data analytics 
platform in England created to address urgent COVID-19-
associated questions, which has been described previously.2 
We used routinely collected electronic data from primary 
care practices using The Phoenix Partnership (TPP) 
SystmOne software. These data cover around 40% of the 
population in England and are linked to Office of National 
Statistics (ONS) death registrations. We included all adults 
(aged ≥18 years) alive and in follow-up on Feb 1, 2020, and 
with at least 1 year of continuous registration with a general 
practitioner (GP) before this date to ensure adequate cap-
ture of baseline data. We excluded people with missing 
age, sex, or index of multiple deprivation, because they 
probably indicate poor quality data.
Procedures
The outcome was COVID-19 death, defined as a record 
for death in linked ONS data with the International 
Classification of Diseases 10 codes U07.1 (COVID-19, 
virus identified) or U07.2 (COVID-19, virus not identified) 
anywhere on the death certificate.12 In a sensitivity 
analysis, we used a stricter outcome defin ition requiring 
confirmed COVID-19 (code U07.1) to be recorded as the 
underlying cause of death.
The main exposure was HIV status, and covariates 
considered in the analysis included age at Feb 1, 2020 
(grouped as 18–39, 40–49, 50–59, 60–69, 70–79 and 
≥80 years for descriptive analysis, and parametrised 
as a four-knot restricted cubic spline in regression 
models), sex, self-reported ethnicity (White, Mixed, 
South Asian, Black, and other), obesity (body-mass 
index [BMI] 30–34·9 kg/m² [class I], 35–39·9 kg/m² 
[class II], and ≥40 kg/m² [class III]), smoking status 
(never, former, and current), index of multiple depriv-
ation quintile (derived from the patient’s postcode 
at lower super output area level), and comorbidities 
considered potential risk factors for severe COVID-19 
outcomes. These comorbidities were hypertension, 
asthma (cate gorised by use of oral steroids), chronic 
respiratory diseases other than asthma, chronic heart 
disease, diabetes (categorised according to the most 
recent glycated haemoglobin recorded in the 15 months 
before Feb 1, 2020), non-haematological and haema-
tological cancer (both categorised by recency of 
diagnosis; <1, 1–4·9, and ≥5 years), reduced kidney 
function (categorised by estimated glomerular filtration 
rate derived from the most recent serum creatinine 
measure; 30–<60 mL/min per 1·73 m² and <30 mL/min 
per 1·73 m²), chronic liver disease, stroke or dementia, 
other neurological disease (motor neurone disease, 
myasthenia gravis, multiple scler osis, Parkinson’s 
disease, cerebral palsy, quadriplegia or hemiplegia, 
and pro gressive cere bellar disease), organ transplant, 
asplenia (splen ectomy or a spleen dysfunction, including 
sickle cell disease), rheumatoid arthritis, lupus, or 
psoriasis, and other immuno suppressive conditions 
(permanent immuno deficiency ever diagnosed or 
aplas tic anaemia or temporary immunodeficiency 
recorded within the past year). Post hoc, we additionally 
adjusted for household size (1–2, 3–5, 6–10, and ≥11) as 
a potential confounder among individuals with data 
available.
Information on HIV and all covariates was obtained by 
searching TPP SystmOne records before Feb 1, 2020, for 
Research in context
Evidence before this study
We searched PubMed on July 20, 2020, for population-based 
epidemiological studies comparing risk of severe COVID-19 
outcomes between people with and without HIV. The search term 
“HIV AND (COVID OR coronavirus OR SARS-CoV-2) AND (rate OR 
hazard OR odds OR risk)” was used, with results filtered to articles 
from the past year with abstracts available, with no language 
restrictions. 78 papers were identified for screening but none 
included the comparison of interest. A relevant study separately 
identified on the medRxiv preprint server found a higher risk of 
COVID-19 mortality among people living with HIV compared 
with the general population in Western Cape, South Africa.
Added value of this study
We used UK primary care data from more than 17 million 
people linked to national death registrations to compare 
risk of COVID-19 death between people with and without HIV. 
People with HIV were at elevated risk of COVID-19 mortality 
compared with the general population without HIV, 
even after accounting for demographic characteristics, 
lifestyle-associated factors, and comorbidities. 
The association was particularly marked among people of 
Black ethnicity.
Implications of all the available evidence
People with HIV in the UK seem to be at increased risk of 
COVID-19 mortality. Targeted policies should be considered 
to address this apparent raised risk as the pandemic response 
evolves. The monitoring and evaluation of the effects of HIV on 
COVID-19 outcomes in countries with a higher prevalence of 
HIV and lower levels of treatment and viral control should be 
prioritised.
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specific coded data, based on a GP subset of SNOMED-CT 
mapped to Read version 3 codes. 83 codes for HIV were 
included, but most people living with HIV were identified 
from four codes: 43C3 HIV positive (73%), X70M6 
HIV infection (10%), Xa0ye HIV (4%), and X80bg HIV 
antibody (4%). People with no HIV code on their primary 
care record at the study start date formed the control 
group. All code lists and detailed information on their 
compilation are avail able online for inspection and use 
by the wider research community.
Statistical analysis
Follow-up time for COVID-19 mortality was from 
Feb 1, 2020, until the date of COVID-19 death or 
June 22, 2020, which was the last date for which mortality 
data were complete. Death from causes other than 
COVID-19 were censored. Thus, our analysis did not 
incorporate the effects of competing risks on cumulative 
incidence, but rather focused on cause-specific hazards,13 
which is an appropriate method for estimating causal 
effects of covariates.14 We used Cox regression models to 
estimate the association between HIV infection and 
COVID-19 mortality, initially unad justed, then cumu-
latively adjusted in sequential models for age and sex, 
index of multiple deprivation and ethni city, and smoking 
and obesity. The model adjusted for all these variables 
would control for confounding under the assumptions 
outlined in the directed acyclic graph pre sented in the 
appendix (p 3). In a subsequent secondary model, we 
added adjustment for all aforementioned comorbidities 
to explore the extent to which any effect of HIV might be 
mediated through these comorbidities, but they were 
considered to be causal pathway variables rather than 
confounders (appendix p 3). Models were stratified by 
the Sustainability and Transformation Partnership (a UK 
National Health Service [NHS] admin istrative region) of 
the patient’s general practice to allow for geographical 
differences in baseline hazards. Multiple imputation 
(ten imputations) was used to account for missing 
ethnicity. A multinomial logistic imputation model 
including all covariates from the main modelling and an 
indicator for the outcome was used to generate the 
imputations, and model estimates from the resulting ten 
imputed datasets were combined by use of Rubin’s rules. 
Individuals with missing BMI were ass umed to be non-
obese, and those with missing smoking data were 
assumed to be never-smokers; we did not use multiple 
imputation for these variables, because they are expected 
to be missing not at random in UK primary care.15 
In sensitivity analyses, we excluded individuals with 
missing data (complete case analysis). Proportional 
hazards were checked first by testing the slope of the 
Schoenfeld residuals (among those with complete eth-
nicity only) and second by fitting an interaction between 
analysis time and the HIV variable. To fit this interaction, 
time was cate gorised as 0–59, 60–89, 90 or more days 
from Feb 1, 2020. These categories were chosen to 
capture the period before social distancing policies in 
the UK would have affected mortality, the period of peak 
COVID-19 mortality, and the period during which 
restrictions began to be eased, because these factors 
might have differentially affected the risk of acquiring 
infection (and thus the overall risk of COVID-19 death) in 
different population subgroups. Collinearity was checked 
by inspecting standard errors in unadjusted and adjusted 
models and calculating variance inflation factors in the 
covariate list in the primary adjusted model. We checked 
that our conclusions were not sensitive to the decision to 
use a time-to-event mod elling framework by re-fitting the 
primary adjusted model using logistic regression with 
the binary outcome of COVID-19 death by June 22.
To investigate variables con sidered a priori to be 
potential effect modifiers, we fitted interaction terms (one 
at a time) between HIV status and age (<60 years and 
≥60 years), sex, ethnicity (Black vs other), and presence of 
comorbidities (any vs none of the comorbidities included 
in the analysis [a sensitivity analysis excluded hyper-
tension, because a past code for hypertension might not 
reflect ongoing disease]) to the main Cox model adjusted 
for age, sex, deprivation, ethnicity, smoking, and obesity. 
These variables were dichotomised owing to reduced 
power. Two-sided p values were from Wald tests on the 
interaction terms.
Cumulative mortality curves, standardised to adjust for 
different covariate distributions in the HIV and non-HIV 
groups, were generated. A Royston-Parmar model with 
the same covariates as the fully adjusted Cox model was 
fitted, with the baseline hazard modelled using a three-
degrees-of-freedom spline.16 The survival function was 
predicted from this model for every individual with HIV 
and averaged to produce the curve for the HIV group. To 
produce the standardised comparison curve, the survival 
functions were predicted and averaged again for the 
same individuals, but with HIV status set to 0.
All statistical analyses were done in Stata version 16.
NHS England is the data controller, TPP is the data 
processor, and the key researchers on OpenSAFELY are 
acting on behalf of NHS England. OpenSAFELY is hosted 
within the TPP environment which is accredited to the 
ISO 27001 information security standard and is NHS IG 
Toolkit compliant.17,18 Patient data are pseudo nymised for 
analysis and linkage using industry standard crypto-
graphic hashing techniques. All pseudonymised datasets 
transmitted for linkage onto OpenSAFELY are encrypted, 
and access to the platform is through a virtual private 
network connection, restricted to a small group of 
researchers who hold contracts with NHS England and 
who only access the platform to initiate database queries 
and statistical models. All database activity is logged; only 
agg regate statistical outputs leave the platform envi ron-
ment following best practice for anonymisation of results, 
such as statistical disclosure control for low cell counts.19 
The OpenSAFELY platform adheres to the data protection 
principles of the UK Data Protection Act 2018 and the EU 
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General Data Protection Regulation 2016. In March, 2020, 
the Secretary of State for Health and Social Care used 
powers under the UK Health Service (Control of Patient 
Information) Regulations 2002 to require organisations 
to process confidential patient information for the 
purposes of protecting public health, providing healthcare 
services to the public and monitoring and managing the 
COVID-19 outbreak and incidents of exposure.20 Taken 
together, these measures provided the legal bases to link 
patient datasets on the OpenSAFELY platform. This study 
was approved by the Health Research Authority (Research 
Ethics Committee reference 20/LO/0651) and by the 
London School of Hygiene & Tropical Medicine Ethics 
Board (reference 21863).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
17 282 905 adults were included; 27 480 (0·16%) were living 
with HIV and 17 255 425 (99·84%) did not have HIV 
(figure 1). People with HIV had similar median age, but a 
narrower age distribution overall, compared with those 
without HIV; there was a substantially lower pro por tion of 
people older than 70 years in the HIV group (1146 [4·2%] 
in those with vs 3 070 564 [17·8%] in those without HIV; 
table 1). People living with HIV were more likely to be 
male, of Black ethnicity, and from a more deprived area. 
921 (3·4%) individuals with HIV had chro nic liver disease, 
compared with 99 214 (0·6%) of those in the comparison 
group.
There were 25 COVID-19 deaths among people 
with HIV during 10 680 person-years of follow-up and 
14 857 COVID-19 deaths among those without HIV 
during 6·70 million person-years of follow-up (table 2). 
68 638 individuals (0·4%) died from non-COVID-19 causes 
and were censored. Between Feb 1 and June 22, 2020, 
estimated cumulative COVID-19 mortality among all study 
partici pants, standardised to the covariate distribution of 
the HIV group, was 0·087% (95% CI 0·056–0·134) in 
people with HIV and 0·038% (0·036–0·040) in people 
without HIV (figure 2).
Crude risk of COVID-19 death was similar in people 
with and without HIV (hazard ratio [HR] 1·03, 95% CI 
0·70–1·52), but after adjusting for age and sex, HIV 
was associated with a nearly three-fold higher risk of 
COVID-19 death (2·90, 1·96–4·30; p<0·0001; figure 3). 
This risk attenuated slightly after further adjustment 
for index of multiple deprivation, ethnicity, obesity, 
and smoking (2·59, 1·74–3·84; p<0·0001). A post-hoc 
adjustment for house hold size among the 15 063 659 indi-
viduals (87·2%) with these data available made little 
difference (2·56, 1·73–3·80). Adjust ment for potentially 
mediating comorbidities reduced the HR slightly (2·30, 
1·55–3·41).
There was some evidence that the association between 
HIV and COVID-19 death was larger in Black individuals 
(HR 4·31, 95% CI 2·42–7·65) than in other ethnic groups 
(1·84, 1·03–3·26; p-interaction=0·044; figure 3). There 
was no statistical evidence of interaction by age, sex, or 
presence of other comorbidities; the point estimate for 
the HIV-mortality association was larger for individuals 
with at least one comorbidity than for those with none, 
but CIs were wide, and excluding hypertension from 
the list of comorbidities attenuated the difference. The 
estimated association between HIV and COVID-19 death 
appeared to be larger early in the epidemic and reduced 
over time, suggesting possible non-proportionality of 
hazards, but it was not statistically significant (p=0·26).
Further assessment for non-proportional hazards 
based on Schoenfeld residuals showed no evidence of 
non-proportionality by HIV status (p=0·32), but there 
was evidence of non-proportional haz ards in several 
adjustment covariates, namely ethni city, sex, obesity, 
smoking, and index of multiple deprivation, so an 
additional sensi tivity analysis was done. This analy sis 
modelled non-proportionality by adding inter action 
terms between each of these variables and time-updated 
Figure 1: Study profile
23 610 525 individuals registered with a general practice 
using The Phoenix Partnership software 
on Feb 1, 2020
 
21 645 194 had at least 1 year of follow-up 
before Feb 1, 2020
17 425 690 were adults aged 18 years or older
17 282 905 included in the study population
27 480 people living with HIV
17 255 425 people without HIV
1 965 331 had less than 1 year of previous 
follow-up
4 219 504 were younger than 18 years 
on Feb 1, 2020
 
142 785 were missing demographic data
or index of multiple deprivation 
 125 age
 258 gender 
142 402 index of multiple 
deprivation
 
14 882 deaths linked to COVID-19 
(Office for National Statistics)
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calendar time and had little effect on the HR for HIV 
(adjusted HR 2·49 [95% CI 1·60–3·87] after adding inter-
action terms vs 2·59 [1·74–3·84] in the main analysis).
Results were also similar in sensitivity analyses using 
a stricter outcome definition (adjusted HR 2·60, 95% CI 
1·71–3·96), using a logistic modelling framework 
(adjusted odds ratio 2·59, 95% CI 1·74–3·84), restricting 
to those with known ethnicity (adjusted HR for 
HIV 2·49, 1·60–3·87), and slightly attenuated among 
those with complete BMI and smoking data (adjusted 
HR 2·19, 1·39–3·43). We found no evidence of 
collinearity in the main adjusted model (variance 
inflation factors all <1·3).
Discussion
In this large population-based study using data from the 
OpenSAFELY platform in England, we found people with 
HIV to be at more than twice the risk of COVID-19 death 
compared with people without HIV, after accounting 
for demographic characteristics and lifestyle-asso ciated 
factors. Absolute cumulative COVID-19 mortality was 
low, with less than 0·1% of people with HIV dying with 
COVID-19 as a cause during the study period, reflecting 
the young age profile of this population. The association 
between HIV and COVID-19 mortality seemed to be 
particularly pronounced among people of Black ethnicity, 
with HIV associated with a 4·3-fold higher risk of 
COVID-19 death in this group.
HIV group 
(N=27 480)
No HIV group 
(N=17 255 425)
Age
18–39 years 6625 (24·1%) 5 908 794 (34·2%)
40–49 years 8486 (30·9%) 2 842 155 (16·5%)
50–59 years 8093 (29·5%) 3 043 868 (17·6%)
60–69 years 3130 (11·4%) 2 390 044 (13·9%)
70–79 years 937 (3·4%) 1 938 734 (11·2%)
≥80 years 209 (0·8%) 1 131 830 (6·6%)
Median (IQR) 48 (40–55) 49 (34–64)
Sex
Male 17 780 (64·7%) 8 614 886 (49·9%)
Female 9700 (35·3%) 8 640 539 (50·1%)
BMI*
Not obese 21 539 (78·4%) 13 488 390 (78·2%)
30–34·9 kg/m² (obese class I) 3777 (13·7%) 2 381 893 (13·8%)
35–39·9 kg/m² (obese class II) 1475 (5·4%) 921 864 (5·3%)
≥40 kg/m² (obese class III) 689 (2·5%) 463 278 (2·7%)
Smoking status†
Never 13 398 (48·8%) 8 634 105 (50·0%)
Former 7922 (28·8%) 5 685 069 (32·9%)
Current 6160 (22·4%) 2 936 251 (17·0%)
Ethnicity
White 12 708 (46·2%) 10 859 301 (62·9%)
Mixed 1390 (5·1%) 168 649 (1·0%)
South Asian 1175 (4·3%) 1021 252 (5·9%)
Black 7143 (26·0%) 332 971 (1·9%)
Other 645 (2·3%) 319 845 (1·9%)
Missing 4419 (16·1%) 4 553 407 (26·4%)
Index of multiple deprivation
1 (least deprived) 2790 (10·2%) 3 494 398 (20·3%)
2 4127 (15·0%) 3 473 416 (20·1%)
3 5108 (18·6%) 3 480 657 (20·2%)
4 6863 (25·0%) 3 475 019 (20·1%)
5 (most deprived) 8592 (31·3%) 3 331 935 (19·3%)
Comorbidities‡
Hypertension 5290 (19·3%) 3 666 002 (21·2%)
Chronic respiratory disease 1095 (4·0%) 703 335 (4·1%)
Chronic heart disease 1444 (5·3%) 1 167 008 (6·8%)
Chronic liver disease 921 (3·4%) 99 214 (0·6%)
Stroke or dementia 559 (2·0%) 389 828 (2·3%)
Other neurological disease 239 (0·9%) 170 336 (1·0%)
Organ transplant 72 (0·3%) 19 933 (0·1%)
Asplenia 89 (0·3%) 27 845 (0·2%)
Rheumatoid arthritis, lupus, 
or psoriasis
1233 (4·5%) 877 666 (5·1%)
Other immunosuppressive 
conditions
53 (0·2%) 4211 (0·0%)
(Table 1 continues in next column)
HIV group 
(N=27 480)
No HIV group 
(N=17 255 425)
(Continued from previous column)
Asthma
With no oral steroid use 3460 (12·6%) 2 454 236 (14·2%)
With oral steroid use 433 (1·6%) 291 606 (1·7%)
Diabetes
With HbA1c <58 mmol/mol 1521 (5·5%) 1 037 513 (6·0%)
With HbA1c ≥58 mmol/mol 739 (2·7%) 485 895 (2·8%)
With no recent HbA1c measure 449 (1·6%) 193 665 (1·1%)
Cancer (non-haematological)
Diagnosed <1 year ago 108 (0·4%) 80 004 (0·5%)
Diagnosed 1–4·9 years ago 372 (1·4%) 233 977 (1·4%)
Diagnosed ≥5 years ago 804 (2·9%) 541 921 (3·1%)
Haematological malignancy
Diagnosed <1 year ago 30 (0·1%) 8691 (0·1%)
Diagnosed 1–4·9 years ago 114 (0·4%) 27 648 (0·2%)
Diagnosed ≥5 years ago 421 (1·5%) 63 076 (0·4%)
Reduced kidney function
Estimated GFR 30–60 mL/min 
per 1·73m²
1427 (5·2%) 1 006 298 (5·8%)
Estimated GFR <30 mL/min 
per 1·73m²
134 (0·5%) 77 964 (0·5%)
Data are n (%) unless otherwise stated. BMI=body-mass index. HbA1c=glycated 
haemoglobin. GFR=glomerular filtration rate. *Missing BMI included in not obese 
(HIV group n=4550, non-HIV group n=3 737 207). †Missing smoking included in 
never smoker (HIV group n=457, non-HIV group n=720 500). ‡The number of 
individuals with any comorbidity (of those listed) was 12 984 (47·3%) in HIV group 
and 7 914 272 (45·9%) in non-HIV group. The number with ever hepatitis C was 
1491 (5·4%) in HIV group and 38 235 (0·2%) in the non-HIV group.
Table 1: Demographic characteristics of people with and without HIV 
in OpenSAFELY
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Few comparable data have been published. Our results 
are similar to those from a large population-based cohort 
study from South Africa involving 3·5 million individuals,8 
which found an adjusted HR of 2·14 (95% CI 1·98–3·43), 
compared with 2·30 (1·55–3·41) in our study. It is note-
worthy that the association was similar in an English 
setting in which levels of antiretroviral treatment and viral 
suppression are higher than in South Africa; however, our 
observation of this association is consistent with stratified 
analyses in the South African data, which found a more 
than doubled risk of COVID-19 death even among those 
with a recent prescription for antiretroviral treat ment and 
a recent viral load measure of less than 1000 copies per 
mL, although limitations of that study included a lack of 
control for socioeconomic status and limited comorbidity 
data. Early data from small cohorts and case series in 
other countries included a large pro portion of patients 
with severe disease.21–23 A single-centre cohort in Madrid, 
Spain, found that, among 51 people living with HIV and 
diag nosed with COVID-19, 28 (55%) required hospital 
admis sion and 13 (25%) had severe disease; the mortality 
rate among COVID-19 cases co-infected with HIV in this 
study was around double that in similarly aged individuals 
in the general population.9 Associations between HIV and 
ad verse COVID-19 outcomes seem to be smaller among 
patients already hospitalised with COVID-19; the HR 
for mortality in the South African study was attenuated 
to 1·45 (1·14–1·84) when restricted to hospitalised 
patients,8 and emerging data on patients hospitalised in 
the UK found a similar association,24 whereas an analysis 
of patients hospitalised in New York found no difference 
in adverse outcomes between HIV infected and uninfected 
indivi duals.11 However, any role that HIV might have in 
increasing the risk of infection or development of severe 
disease is effectively conditioned out by restriction to 
hospitalised individuals who are already infected with 
SARS-COV-2 and who probably have severe disease at the 
point of inclusion.25
The larger association between HIV and COVID-19 
death among people of Black ethnicity has not 
previously been described. We have previously shown a 
larger overall risk of COVID-19 death in Black and 
minority ethnic (BAME) compared with white groups 
in England,2 and a systematic review suggested that 
BAME individuals might have a higher risk of ac-
quiring COVID-19 infection and having worse clinical 
outcomes.26 HIV infection could plausibly exacerbate 
both, although it is not possible to delineate from our 
study which parts of the pathway are more or less 
affected by HIV status. BAME individuals are also at 
higher risk of negative HIV outcomes, including 
virological rebound.27 Under standing the reasons for 
the disproportionately large association between HIV 
and COVID-19 mortality in this group will be a priority 




No HIV group 
(N=14 857)
Age
<60 years 10 (40%) 901 (<1%)
≥60 years 15 (60%) 13 956 (94%)
Sex
Male 18 (72%) 8110 (55%)
Female 7 (28%) 6747 (45%)
Body-mass index
Not obese 15 (60%) 11 044 (74%)
Obese 10 (40%) 3813 (26%)
Ethnicity
Black* 11 (44%) 284 (2%)
White, other, or unknown 14 (56%) 14 573 (98%)
Common comorbidities†
Hypertension 15 (60%) 9752 (66%)
Diabetes 14 (56%) 5372 (36%)
Reduced kidney function‡ 9 (36%) 6659 (45%)
Any comorbidity (including 
hypertension)§
23 (92%) 13 897 (94%)
Any comorbidity (excluding 
hypertension)§
21 (84%) 13 168 (89%)
*Self-report as African, Caribbean or other Black. †All other individual comorbidities 
were present in five or fewer individuals in the HIV group and are redacted as per 
our protocol. ‡Estimated glomerular filtration rate <30 mL/min per 1·73 m². §From 
comorbidites listed in table 1.
Table 2: Characteristics of people who died with COVID-19 as a listed 
cause of death
Figure 2: Cumulative COVID-19 mortality during the study period by HIV 
status with 95% CI, standardised to covariate distribution of the HIV group
Note that cumulative COVID-19 mortality is not restricted to individuals 
infected with severe acute respiratory syndrome coronavirus 2 but rather 
represents the cumulative incidence of acquiring infection and then progressing 
to death with COVID-19 listed as a cause. Cumulative mortality predicted from 
a Royston-Parmar model including age, sex, index of multiple deprivation, 
ethnicity, smoking, and obesity, with the baseline hazard parametrised as a 
three-degrees-of-freedom cubic spline; predictions standardised to the covariate 
distribution of the HIV group. This analysis was done for individuals with 
complete ethnicity data only, because computational limitations prevented 
implementation in the dataset with multiply imputed ethnicity.
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Our study was large, with sufficient power to estimate 
the association between HIV and COVID-19 death, 
accounting for demo graphic characteristics, lifestyle-
associated factors, inclu ding BMI and smoking, and 
relevant comorbidities. We tested the robustness of our 
findings to different missing data approaches and to non-
propor tional hazards. We investigated effect modification 
by key covariates and were able to detect differences by 
ethnicity. However, the relatively small number of deaths 
among individuals with HIV, reflecting the young age 
distri bution of the HIV group, prevented definitive 
conclusions about the role of comorbidities and changes 
in the role of HIV over time. Among people with no 
comorbidities, those with HIV had no observed increase 
in risk of COVID-19 death, but the non-significant 
interaction was inconclusive given reduced power. We 
also noted a suggestion of a larger association between 
HIV and COVID-19 death early in the epidemic. If 
confirmed, this finding might suggest a higher risk 
of infection before widespread social distancing was 
introduced, but we could not rule out that it reflected 
chance variation. Analysis of pre-mortality indicators of 
severe disease, such as hospitalisation, would have 
greater statistical power to clarify this, but we could not 
obtain linked hospital data for people living with HIV, 
because HIV codes are considered sensitive in NHS data 
and transfer is legally restricted.28
For similar reasons, we were unable to include data on 
antiretroviral therapy use, viral suppression, CD4 count, 
or previous AIDS-defining illnesses likely to be captured 
only in specialist care, so it was not possible to stratify 
results or quantify how much of the increased risk was 
driven by the minority of individuals with poorly con-
trolled HIV. HIV in the UK is commonly managed in 
specialist clinics, but restrictions on the sharing of 
HIV-associated codes and policy guidance that cautions 
against sharing HIV-associated information with patients’ 
primary care providers meant that we could not access 
key data from routine HIV care. Nevertheless, we do not 
consider the absence of these data to substantially 
undermine the utility of our findings, given that 94% of 
diagnosed HIV-positive individuals in the UK are on 
antiretrovirals and have good viral suppression (97% on 
therapy, and 97% of these with undetectable viral load).29 
The association between HIV and COVID-19 death is 
unlikely to have been driven entirely by the 6% assumed 
untreated or with detectable viral load; if all deaths had 
been within this group, it would amount to more 
than 1·5% becoming infected and dying from COVID-19, 
compared with less than 0·01% of the general population. 
There are no available routinely collected data on 
injection drug use, occupation, or contact patterns. HIV 
diagnoses recorded in primary care are expected to be 
highly specific, but some under-ascertainment is 
possible; this should have had little effect, because 
HIV-positive people misclassified as HIV-negative would 
have made up only a tiny proportion of our comparator 
group. Any resulting bias is likely to have been towards 
the null, particularly if high-risk people not engaged 
with primary care were more likely to be missed. We 
included clinically suspected (non-laboratory confirmed) 
COVID-19 deaths; because there was little testing early in 
the pandemic, some non-COVID-19 deaths might have 
been misclassified as COVID-19 deaths. We assume any 
such misclassification will have been non-differential 
with respect to HIV status, which could again have led to 
bias towards the null, but given that more than 90% of 
COVID-19 deaths in our analysis had a code indicating 
that SARS-CoV-2 infection was laboratory confirmed, any 
such bias is likely to be small. Although we included 
deaths with a COVID-19 code any where on the death 
certificate, more than 90% of outcomes had COVID-19 
entered as the underlying cause of death. A sensitivity 
analysis restricting outcomes to confirmed COVID-19 
listed as the underlying cause of death gave similar 
results to the primary analysis. There might have 
been some informative censoring if indivi duals censored 
Figure 3: HRs for the association between HIV and COVID-19 mortality
All stratified models (by age, sex, ethnicity, comorbidities, epidemic period) were adjusted for age, sex, IMD, 
ethnicity. IMD=index of multiple deprivation. HR=hazard ratio. *Black is defined as self-report as African, Caribbean, 
or other Black; a similar pattern was seen in a direct comparison between Black (HR 4·81, 95% CI 2·63–8·80) and 
white (2·02, 1·05–3·89) among individuals with complete ethnicity data. †Comorbidities refers to diagnosed 
hypertension, chronic respiratory disease, asthma, chronic cardiac disease, diabetes, non-haematological cancer, 
haematological cancer, chronic liver disease, stroke and dementia, other neurological disease, reduced kidney 
function, organ transplant, asplenia, rheumatoid arthritis, lupus, and psoriasis, and other immunosuppressive 
conditions; the model stratified by comorbidities was additionally adjusted for these comorbidities as individual 
covariates; excluding hypertension from the list of comorbidities gave stratified HRs of 1·57 (0·59–4·20) for 
individuals without comorbidities and 2·52 (1·64–3·87) for those with comorbidities (p-interaction=0·39). 
‡Days from Feb 1, 2020; the three categories were chosen to capture the period before social distancing policies 
in the UK would have affected mortality, the period of peak COVID-19 mortality, and the period during which 
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owing to death without COVID-19 were also at higher 
risk of COVID-19 death, but adjustment for age (the 
most important risk factor for both COVID-19 and 
non-COVID-19 death) should have minimised this. 
Imperfect measurement of adjustment covariates could 
have led to some residual confounding; for example, 
index of multiple deprivation quintile is unlikely to have 
perfectly captured all confounding due to socio economic 
factors. Our study population, derived from one elec-
tronic health record software system, is not fully geo-
graphically representative of the broader population 
of England. In particular, London, which has a relatively 
high prevalence of HIV nationally, is under-represented 
in our data.
Our findings suggest that people living with HIV might 
be a high-risk group for COVID-19 death, indi cating a 
need to consider targeted policies for this group. People 
living with HIV might also need priority consider ation 
if and when a vaccine against SARS-CoV-2 becomes 
available. Our findings might also have impli cations 
globally. Levels of antiretroviral therapy use and viral 
suppression in England are high, whereas prevalence of 
HIV is relatively low in global terms;29 the impact of HIV 
on the progression of the pandemic in other settings will 
need to be carefully monitored. Future studies should 
prioritise better understanding of the drivers of increased 
COVID-19 mortality among people living with HIV and 
the role of ethnicity. Although it is of particular interest to 
separate how HIV status affects risk of SARS-CoV-2 
infection versus progression to severe disease or 
death once infected, this is challenging, because most 
SARS-CoV-2 testing is focused on individuals at high risk 
or with symptoms and unlikely to capture those with 
mild or asymp tomatic infection; should mass population-
level testing become widespread this will be a more 
achievable research priority. Future studies might also 
prioritise assessing how the association between HIV and 
severe COVID-19 out comes is affected by comorbidities 
(including consider ation of hypothesised premature 
ageing among people living with HIV30), viral load, CD4 
count, and antiretroviral treatment. In England, despite a 
strong overall infra structure of linkable electronic health 
records data, research is hampered by policy guidance 
that has generally led to restrictions in the sharing and 
flow of HIV-associated data, despite apparent support for 
sharing for public health purposes.31 We propose a review 
of guidance to ensure that people living with HIV are not 
unnecessarily excluded from research.
In this large population-based study, people living 
with HIV in England had an elevated risk of COVID-19 
death after accounting for demographic characteristics 
and lifestyle-associated factors. Absolute cumulative 
COVID-19 mortality was relatively low, reflecting the 
young age profile of the population of people living 
with HIV. Monitoring the role of HIV in COVID-19 
outcomes in other settings will be crucial as the 
pandemic pro gresses.
For OpenSAFELY see 
https://opensafely.org/
For code see https://github.com/
opensafely/hiv-research
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